PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Alligator Bioscience gains orphan designation for mitazalimab

Mitazalimab is a monoclonal antibody that has been created to sensitize tumours to chemotherapy.

Alligator Bioscience has announced that the European Medicines Agency (EMA) has granted orphan designation for the company’s lead asset, mitazalimab, for the treatment of pancreatic cancer.

Mitazalimab is a monoclonal antibody targeting CD40 and has been created to sensitize tumours to chemotherapy while also inducing immune-mediated tumour killing by activating dendritic cells, B cells and macrophages.

At present, the drug is being evaluated in OPTIMIZE-1, a phase 2 multi-location, open-label trial to analyse efficacy and safety when combined with chemotherapy (mFOLFIRINOX) in previously untreated patients with metastatic pancreatic ductal adenocarcinoma.

In June, Alligator announced a second set of strong interim results from OPTIMIZE-1, during which mitazalimab combined with mFOLFIRINOX demonstrated a deepening of tumour reaction and an increase in objective response rate (ORR) to 57% (it was initially 52% ORR among the 23 patients involved).

To meet the criteria for the EMA’s orphan designation, therapy must be delivered for the treatment, prevention or diagnosis of rare, life-threatening or chronically debilitating diseases that impact fewer than five in 10,000 individuals across the EU.

Treatments that qualify are eligible for financial and regulatory incentives that include ten years of marketing exclusivity throughout the EU after a product has been approved.

Søren Bregenholt, chief executive officer at Alligator Bioscience, reflected: “We are very pleased that the European Medicines Agency has granted orphan designation to our lead asset mitazalimab in the treatment of pancreatic cancer.”

He added: “It is our second orphan designation this year following the US Food and Drug Administration’s (FDA) decision to grant us ODD in May, meaning mitazalimab now has stronger commercial protection through market exclusivity in these two key markets. This latest designation adds to the momentum we are building in our efforts to bring this promising drug candidate to market.”

Earlier this year, the FDA provided orphan drug designation to mitazalimab for treating pancreatic cancer.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026